FDA Approves Novartis's Exforge to Lower Hypertension

For some high blood pressure patients, the use of a prescription drug known as Exforge, distributed by Novartis Pharmaceuticals, has become more common in the approach to controlling high blood pressure with an FDA approved medication.

Exforge has shown to be effective at controlling high blood pressure through its combination approach of amlodipine and valsartan, applying vasoconstriction therapy and calcium channel blocker.Dosing of Exforge tablets, in the treatment of high blood pressure, is recommended as a combination of both 2.5 to 10 milligrams of amlodipine in combination with 80 to 320 milligrams of valsartan, once per day. When titrated for optimal therapeutic benefit, most patients do not require much adjustment to maintain that optimal treatment for 24 hours.

Novartis, the Swiss drug manufacturer, has received final approval for its Exforge product from the US Food and Drug Administration. Exforge, a medicine for sufferers of high blood pressure, merges together, in a single tablet, the two hypertension medicines most often prescribed at present.
This duo Diovan, produced by Novartis, and the Pfizer-made Norvasc – are combined into a formula which, in clinical trials, resulted in 90 per cent of those tested attaining their individual hypertension treatment goals.
Commenting on the positive news, Novartis stated that Exforge would, as a consequence, soon be available on the US market.

Exforge is a new antihypertensive medication produced by Novartis pharma. It combines between two main antihypertensive classes (Angiotensin Receptor Blockers as Valsartan and Calcium channel Blockers as Amlodipine). It’s been prescribed by doctors in case of chronic high blood pressure when one drug is not enough.